{"id":"NCT01146951","sponsor":"Eisai Limited","briefTitle":"A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)","officialTitle":"A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2010-06-22","resultsPosted":"2013-11-21","lastUpdate":"2018-01-24"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lennox-Gastaut Syndrome"],"interventions":[{"type":"DRUG","name":"Rufinamide (E2080)","otherNames":["E2080"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rufinamide (E2080)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.","primaryOutcome":{"measure":"Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)","timeFrame":"Baseline (28 day observational period) and End of Treatment (28 day treatment period)","effectByArm":[{"arm":"Rufinamide (E2080)","deltaMin":-24.2,"sd":null},{"arm":"Placebo","deltaMin":-3.25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":23,"countries":["Japan"]},"refs":{"pmids":["33825230","33179247"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":29},"commonTop":["Nasopharyngitis","Status Epilepticus","Decreased Appetite","Somnolence","Vomiting"]}}